BeOne Medicines (NASDAQ:ONC) Stock Rating Lowered by Wall Street Zen

BeOne Medicines (NASDAQ:ONC) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

ONC has been the subject of a number of other reports. Royal Bank Of Canada raised their target price on shares of BeOne Medicines from $417.00 to $425.00 and gave the company an “outperform” rating in a report on Thursday. Truist Financial lifted their price objective on shares of BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday. Citizens Jmp upped their target price on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Barclays lifted their price target on BeOne Medicines from $394.00 to $405.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Jefferies Financial Group restated a “buy” rating and set a $420.00 price objective on shares of BeOne Medicines in a research report on Monday, November 17th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.25.

BeOne Medicines Trading Down 1.7%

Shares of BeOne Medicines stock opened at $316.99 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The firm has a market cap of $34.76 billion, a price-to-earnings ratio of 125.79 and a beta of 0.53. BeOne Medicines has a twelve month low of $196.45 and a twelve month high of $385.22. The business has a 50-day moving average price of $336.81 and a 200-day moving average price of $330.87.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). BeOne Medicines had a net margin of 5.37% and a return on equity of 11.10%. The firm had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. Equities research analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Activity

In other BeOne Medicines news, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Oyler sold 75,631 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $307.79, for a total value of $23,278,465.49. Following the completion of the sale, the chief executive officer owned 24,369 shares in the company, valued at approximately $7,500,534.51. The trade was a 75.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 102,656 shares of company stock worth $31,567,496 over the last quarter. 6.62% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds have recently bought and sold shares of the business. Compound Planning Inc. purchased a new stake in BeOne Medicines in the fourth quarter worth $223,000. Invesco Ltd. grew its holdings in shares of BeOne Medicines by 1,008.6% in the fourth quarter. Invesco Ltd. now owns 14,123 shares of the company’s stock worth $4,291,000 after purchasing an additional 12,849 shares during the last quarter. Corient Private Wealth LLC increased its stake in BeOne Medicines by 25.9% in the 4th quarter. Corient Private Wealth LLC now owns 1,064 shares of the company’s stock worth $323,000 after buying an additional 219 shares during the period. Vident Advisory LLC increased its stake in BeOne Medicines by 20.4% in the 4th quarter. Vident Advisory LLC now owns 2,052 shares of the company’s stock worth $623,000 after buying an additional 347 shares during the period. Finally, XTX Topco Ltd bought a new stake in BeOne Medicines during the 4th quarter valued at about $2,912,000. Institutional investors own 48.55% of the company’s stock.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.